Triptorelin
Also known as: Triptorelin pamoate, Triptorelin acetate, GnRH agonist
A GnRH (gonadotropin-releasing hormone) agonist used medically for prostate cancer, endometriosis, precocious puberty, and fertility treatments. Causes initial hormone surge followed by suppression.
Research Status
Extensive Clinical Data
For research purposes only. Not approved for human use. Not medical advice.
Research Areas
Side Effects
Occurs within 24-48 hours of first injection. Symptoms include temporary worsening of existing condition (increased bone pain in prostate cancer, increased endometriosis pain, accelerated puberty in precocious puberty). Usually resolves within 1-2 weeks. Can be mitigated by co-administering an antiandrogen (e.g., bicalutamide) or GnRH antagonist for 1-2 weeks.
Results from estrogen/androgen suppression. More pronounced in females. May persist throughout treatment. Managed with lifestyle modifications or, if severe, selective serotonin reuptake inhibitors (SSRIs) such as venlafaxine.
Direct consequence of testosterone suppression in males. Typically reversible upon treatment discontinuation. Counseling and expectation-setting recommended.
Results from estrogen suppression in females. Managed with vaginal moisturizers or lubricants. May improve with add-back hormone therapy if prolonged treatment is planned.
Occurs with prolonged suppression of sex hormones. Risk increases with treatment duration >6 months. Baseline and periodic DEXA scans recommended. Calcium, vitamin D supplementation, and weight-bearing exercise advised. Add-back hormone therapy may be considered for long-term use.
Associated with hormonal suppression and hypogonadal state. Monitor for depressive symptoms. Psychiatric evaluation recommended if symptoms emerge or worsen.
Usually self-resolving. May be related to initial hormone surge or hormonal fluctuations.
Local pain, erythema, or induration at injection site. Minimize by rotating sites, using proper injection technique, and allowing solution to reach room temperature.
More common during initial flare reaction. Usually self-resolving within 1-2 weeks.
Paradoxical effect due to initial LH surge and peripheral aromatization of androgens. Typically transient and resolves with continued suppression.
Anaphylaxis or severe hypersensitivity reactions are rare but possible. Seek immediate medical attention if rash, difficulty breathing, or angioedema develops.
Rare but life-threatening hemorrhage or infarction of the pituitary gland, typically in patients with pre-existing pituitary adenoma. Presents with sudden severe headache, vision changes, or loss of consciousness. Requires emergency medical evaluation.
Risk during initial flare reaction in patients with metastatic prostate cancer involving the spine. Presents with back pain, leg weakness, or bowel/bladder dysfunction. Requires urgent imaging and intervention.
Hormonal suppression may affect glucose metabolism and lipid profiles. Monitor blood glucose and lipids, especially in patients with diabetes or metabolic syndrome.
Related to hormonal suppression and hypogonadal state. May improve with time or add-back hormone therapy.
Dosing Reference
| Parameter | Value |
|---|---|
| Dose range | 0.1-3.75 mg |
| Frequency | Single dose or monthly depot |
| Timing | As prescribed by physician |
| Route | Subcutaneous |
Dosage depends on indication: 0.1 mg single dose for diagnostic testing; 3.75 mg monthly for therapeutic use. Subcutaneous or intramuscular injection. FDA-approved medication. Must be medically supervised.
Research disclaimer
Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.
Reconstitution Guide
Do not use saline or bacteriostatic saline — use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2–8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration
Molecular and Pharmacological Data
| Molecular weight | 1311.5 g/mol |
| Half-life | 2.6-3 hours (free peptide); 30-40 days (depot formulation) |
| Sequence | pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2 |
Triptorelin is a synthetic GnRH (gonadotropin-releasing hormone) agonist that initially stimulates the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), causing a transient surge in gonadal hormones (testosterone in males, estrogen in females). With continuous exposure, the pituitary becomes desensitized and downregulates GnRH receptors, leading to sustained suppression of LH and FSH secretion and subsequent suppression of gonadal hormone production. This biphasic response — initial surge followed by suppression — is the basis for its therapeutic effects in hormone-dependent conditions.
GnRH Receptor Signaling
Triptorelin binds to GnRH receptors on pituitary gonadotroph cells with high affinity and prolonged duration, triggering initial LH and FSH release followed by receptor desensitization and downregulation.
Hypothalamic-Pituitary-Gonadal (HPG) Axis Suppression
Continuous GnRH agonist stimulation causes pituitary desensitization, reducing endogenous GnRH secretion feedback and suppressing gonadotropin release, ultimately decreasing testosterone and estrogen production.
Androgen Deprivation in Prostate Cancer
Suppression of testosterone production reduces androgen-dependent prostate cancer cell proliferation and growth.
Estrogen Suppression in Endometriosis
Reduced estrogen levels decrease endometrial proliferation and inflammation associated with endometriosis lesions.
- GnRH agonists cause an initial LH and FSH surge (flare reaction) within 24-48 hours before suppression occurs
- Continuous exposure leads to pituitary receptor desensitization and downregulation, suppressing gonadotropin secretion
- Testosterone suppression in males typically reaches castrate levels (<50 ng/dL) within 2-4 weeks
- Estrogen suppression in females creates a hypogonadal state similar to menopause
- Triptorelin is a decapeptide with D-tryptophan substitution at position 6, conferring resistance to enzymatic degradation and prolonged activity
- Depot formulations (pamoate salt) provide sustained release over 1, 3, or 6 months depending on formulation
Track your Triptorelin research
Free account. No credit card required.
Browse the Research Library
40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.
View all peptidesResearch Use Only. All content on this page is provided for informational and educational purposes related to scientific research. Triptorelin is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.